Bromelains is a Enzyme owned by MediWound, and is involved in 15 clinical trials, of which 13 were completed, and 2 are ongoing.

Bromelain is a debridement agent which contains mixture of enzymes that digest protein. The drug candidate has fibrinolytic and proteolytic activity by which it facilitates the reabsorption of hematic effusions. The proteolytic enzymes present in the drug candidate act by dissolving the burn wound eschar (dead and damaged tissues) without harming the healthy tissues which may prove to be effective in treating the disease condition.

The revenue for Bromelains is expected to reach a total of $171m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bromelains NPV Report.

Bromelains is currently owned by MediWound. Vericel and Kaken Pharmaceutical are the other companies associated in development or marketing of Bromelains.

Bromelains Overview

Bromelains (NexoBrid) is a protein extract derived from the stems of Pineapples, Ananas comosus. It is formulated as powder and gel for cutaneous route of administration. It is indicated for removal of eschar in adults with deep partial and full-thickness thermal burns.

The drug candidate is under development for the treatment of severe burns, sulfur mustard (chemical warfare agent) injuries in the U.S., EU, Japan and India. The development of the drug candidate is based on proteolytic enzymatic technology.

Kaken Pharmaceutical Overview

Kaken Pharmaceutical (Kaken) is a specialty pharmaceutical company that conducts research and development of drugs, agrochemicals and medical equipments. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infections and pain relief. Kaken also offers fungicides, rice herbicide, anti-coccidial for chickens and polypeptide antibiotics. The company conducts research in inflammation and immunology, neurological pain relief and fungal infection areas. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY76,034 million for the fiscal year ended March 2022 (FY2022), an increase of 1.4% over FY2021. In FY2022, the company’s operating margin was 17.4%, compared to an operating margin of 23.6% in FY2021. In FY2022, the company recorded a net margin of 12.6%, compared to a net margin of 17.9% in FY2021. The company reported revenues of JPY18,622 million for the second quarter ended September 2022, an increase of 2.3% over the previous quarter.

Quick View – Bromelains

Report Segments
  • Innovator (NME)
Drug Name
  • Bromelains
Administration Pathway
  • Cutaneous
  • Topical
Therapeutic Areas
  • Dermatology
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.